drug_type
RELEVANT_DRUG
intervention_type
Biologic (autologous CAR T-cell therapy)
drug_description
Autologous, second-generation bispecific CAR T-cell therapy targeting CD19 and CD20; utilizes CD3 zeta signaling and 4-1BB costimulation to enhance T-cell activation, expansion, and persistence; administered as a single IV infusion after lymphodepletion for relapsed/refractory large B-cell lymphoma.
nci_thesaurus_concept_id
C178452
nci_thesaurus_preferred_term
Prizloncabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous T-lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, prizloncabtagene autoleucel targets and binds to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a second-generation bispecific CAR that recognizes CD19 and CD20 on B-cell malignancies. Antigen binding activates CD3 zeta signaling to drive T-cell cytotoxicity, while the 4-1BB costimulatory domain enhances expansion and persistence, leading to depletion of malignant (and normal) B cells and helping prevent antigen-escape relapse.
drug_name
Prizloncabtagene autoleucel
nct_id_drug_ref
NCT05800977